News articles about TrovaGene (NASDAQ:TROV) have been trending somewhat positive this week, Accern reports. Accern ranks the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. TrovaGene earned a media sentiment score of 0.07 on Accern’s scale. Accern also assigned news coverage about the medical research company an impact score of 45.3125876171384 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Here are some of the media stories that may have impacted Accern Sentiment’s rankings:

TrovaGene (NASDAQ TROV) traded up $0.01 on Friday, hitting $0.32. The stock had a trading volume of 577,189 shares, compared to its average volume of 1,800,000. The company has a market capitalization of $16.79, a PE ratio of -0.32 and a beta of 0.26. TrovaGene has a 1-year low of $0.23 and a 1-year high of $2.10.

Several brokerages have commented on TROV. ValuEngine raised TrovaGene from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. HC Wainwright began coverage on TrovaGene in a research report on Thursday, December 21st. They issued a “buy” rating and a $1.00 price target on the stock. Maxim Group reaffirmed a “hold” rating on shares of TrovaGene in a research report on Wednesday, January 24th. Finally, downgraded TrovaGene from a “buy” rating to a “hold” rating in a research report on Wednesday, November 15th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $3.70.

COPYRIGHT VIOLATION WARNING: “TrovaGene (TROV) Getting Somewhat Favorable Press Coverage, Accern Reports” was originally posted by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright & trademark law. The original version of this piece of content can be accessed at

TrovaGene Company Profile

Trovagene, Inc is a clinical-stage, precision medicine oncology therapeutics company. The Company’s lead drug candidate, PCM-075, is a Polo-like Kinase 1 (PLK1) selective adenosine triphosphate (ATP) competitive inhibitor. PCM-075 has shown preclinical antitumor activity as a single agent and in synergy combinations with more than ten different chemotherapeutics and targeted therapies, such as Zytiga (abiraterone acetate), Beleodaq (belinostat), Quizartinib (AC220), a development stage FLT3 inhibitor, and Velcade (bortezomib) in Acute Myeloid Leukemia (AML), metastatic Castration-Resistant Prostate Cancer (mCRPC) and other liquid and solid tumor cancers.

Insider Buying and Selling by Quarter for TrovaGene (NASDAQ:TROV)

Receive News & Ratings for TrovaGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene and related companies with's FREE daily email newsletter.